Glenmark launches generic Seretide Accuhaler in Denmark

16 May 2018 Evaluate

Glenmark Pharmaceuticals Europe (Glenmark) has launched a generic version of Seretide Accuhaler in Denmark. This is Glenmark’s first inhaled respiratory product launch in Europe. Glenmark is the first generic company to receive regulatory approval for substitution in Denmark for its generic of Seretide Accuhaler.

Glenmark had entered into a strategic development & licensing agreement with Celon Pharma S.A. (Celon) to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - Fluticasone/Salmeterol dry powder inhaler in 15 European countries. Fluticasone/Salmeterol dry powder inhaler is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Glenmark has already received National Marketing Authorizations for the product in Sweden, Finland, Norway and Iceland. According to IQVIA data, Fluticasone/Salmeterol Dry powder Inhaler (DPI) had sales of $864 million in Europe in the 12 month period ending September 2017.

Glenmark Pharma Share Price

1977.35 6.60 (0.33%)
27-Jan-2026 12:21 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1629.80
Dr. Reddys Lab 1240.80
Cipla 1310.25
Zydus Lifesciences 889.80
Lupin 2141.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×